Subscribe to Newsletter


Reset Filter
You have a filtered search result

264 search results for ‘*’

Discovery & Development Dosage Forms

Gilead Goes Ferreting

| Angus Stewart

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

Manufacture Vaccines

What's Going On in Vaccines?

| Stephanie Vine

The latest issue of The Bioprocess Curator included a lot of interesting news about vaccines. In case you missed it, here's some of the top stories.

Business & Regulation COVID-19

R&R for an Anti-COVID Europe

| Angus Stewart

The EMA has given the nod to Ronapreve and Regkirona, two monoclonal antibody treatments for COVID-19.

Discovery & Development Technology and Equipment

+1 Level Up

| Angus Stewart

Jan Cools of the VIB Center for Cancer Biology discusses his experience with Mission Bio’s new DNA sequencing platform.

Business & Regulation Clinical Trials

Paranoid or Prepared?

| Angus Stewart

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

Manufacture Small Molecules

Synthesizing Synthesis

| Angus Stewart

A possible fix for problems in small molecule manufacture via continuous flow processing.

Discovery & Development Vaccines

Backwards Vax Moves Forward

| Angus Stewart

A University of Buffalo team has produced a reverse vaccination to help manage the symptoms of various chronic and autoimmune conditions.

Discovery & Development Drug Discovery

Closer to the Boundary

| Angus Stewart

A Korean team have conducted a study on a peptide that could help to produce medicines capable of crossing cell membranes and interfering with PPIs.

Business & Regulation Standards & Regulation

The Price Ain’t Right

| Angus Stewart

We speak with the authors of two studies into extreme increases in US drug pricing, and attempts by lawmakers to bring the price-jackers into line.

Discovery & Development Drug Discovery

Painted Cells and Scrambled Jigsaws

| Angus Stewart

Work at the Max Planck Institute of Molecular Physiology has revealed a welcome surprise: a potential new class of COVID-19 drugs.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine